| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Mogroside IV targets multiple pathways. It exhibits maltase inhibitory activity with an IC50 of 10 mM. It also acts as a Toll-Like Receptor-4 (TLR4) agonist and an immune stimulant. It has antioxidant, antidiabetic, and anticancer activities.
|
|---|---|
| ln Vitro |
In vitro, Mogroside IV demonstrates significant biological activity. It exhibits maltase inhibitory activity with an IC50 of 10 mM. It has antioxidant and antidiabetic properties. Its ability to inhibit maltase suggests a potential role in managing postprandial blood glucose levels by slowing carbohydrate digestion.
|
| ln Vivo |
In vivo, Mogroside IV is used in research to study natural sweetener biosynthesis, glycosylation pathways, and structure-activity relationships. As a TLR4 agonist and immune stimulant, it has potential for therapeutic vaccine design in cancer and for other pathogenic agents. Its antidiabetic and antioxidant effects are believed to contribute to the health benefits of monk fruit.
|
| Enzyme Assay |
The in vitro enzyme inhibition assay for Mogroside IV involves measuring its ability to inhibit maltase activity. The enzyme is incubated with a maltose substrate in the presence of varying concentrations of the compound. The amount of glucose produced is measured using a colorimetric method, and the IC50 is calculated from the inhibition curve.
|
| Cell Assay |
In vitro cell culture studies for Mogroside IV utilize various cell lines to study its bioactivity. Its anticancer activity is assessed in cancer cell lines using MTT assays. Its immunomodulatory effects can be studied in immune cells by measuring cytokine production. Its effect on glucose metabolism can be studied in intestinal epithelial cells by measuring glucose uptake.
|
| Animal Protocol |
In vivo animal experiments for Mogroside IV are not extensively documented. However, its immunostimulatory effects could be studied in animal models of cancer or infection. Its antidiabetic effects could be studied in rodent models of type 2 diabetes. Its metabolism and pharmacokinetics could be studied in animal models.
|
| ADME/Pharmacokinetics |
Mogroside IV has a molecular formula of C54H92O24 and a molecular weight of 1125.29 g/mol. It is a solid compound that is soluble in water and organic solvents like DMSO. As a glycoside, it is highly polar. It is typically stored as a powder at -20°C for long-term stability. Its stability is maintained under recommended storage conditions.
|
| Toxicity/Toxicokinetics |
Toxicological data for Mogroside IV are limited, as it is a research compound. As a natural component of monk fruit, it is generally recognized as safe for human consumption at dietary levels. However, as a research compound, it is not intended for therapeutic use, and comprehensive toxicity studies are not available. Standard safety precautions should be followed.
|
| References | |
| Additional Infomation |
Reports indicate that Siamese marigold (Siraitia siamensis) and Grosvenorii (Siraitia grosvenorii) contain mogroside IVe, and relevant data is available for reference.
Mogroside IV is a research compound with no clinical approval. It is a valuable tool for studying the pharmacology of mogrosides and their potential applications in metabolic diseases and immunology. Its maltase inhibitory, antioxidant, and antidiabetic properties make it a compound of interest for research into diabetes and obesity. Its TLR4 agonist activity makes it a potential candidate for vaccine adjuvants. |
| Molecular Formula |
C54H92O24
|
|---|---|
| Molecular Weight |
1125.2939
|
| Exact Mass |
1124.597
|
| CAS # |
89590-95-4
|
| PubChem CID |
102004786
|
| Appearance |
White to off-white solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
1179.3±65.0 °C at 760 mmHg
|
| Flash Point |
667.0±34.3 °C
|
| Vapour Pressure |
0.0±0.6 mmHg at 25°C
|
| Index of Refraction |
1.632
|
| LogP |
1.4
|
| Hydrogen Bond Donor Count |
16
|
| Hydrogen Bond Acceptor Count |
24
|
| Rotatable Bond Count |
17
|
| Heavy Atom Count |
78
|
| Complexity |
2030
|
| Defined Atom Stereocenter Count |
30
|
| SMILES |
C[C@H](CC[C@H](C(C)(C)O)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)[C@H]3CC[C@@]4([C@@]3(C[C@H]([C@@]5([C@@H]4CC=C6[C@H]5CC[C@@H](C6(C)C)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO[C@H]8[C@@H]([C@H]([C@@H]([C@H](O8)CO)O)O)O)O)O)O)C)O)C)C
|
| InChi Key |
WRPAFPPCKSYACJ-KGFBLRRZSA-N
|
| InChi Code |
InChI=1S/C54H92O24/c1-22(9-13-33(51(4,5)70)77-49-45(41(66)36(61)28(20-57)74-49)78-48-44(69)39(64)35(60)27(19-56)73-48)23-15-16-52(6)30-12-10-24-25(54(30,8)31(58)17-53(23,52)7)11-14-32(50(24,2)3)76-47-43(68)40(65)37(62)29(75-47)21-71-46-42(67)38(63)34(59)26(18-55)72-46/h10,22-23,25-49,55-70H,9,11-21H2,1-8H3/t22-,23-,25-,26-,27-,28-,29-,30-,31-,32+,33-,34-,35-,36-,37-,38+,39+,40+,41+,42-,43-,44-,45-,46-,47+,48+,49+,52+,53-,54+/m1/s1
|
| Chemical Name |
(2R,3R,4S,5S,6R)-2-[[(2R,3S,4S,5R,6R)-6-[[(3S,8R,9R,10R,11R,13R,14S,17R)-17-[(2R,5R)-5-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-hydroxy-6-methylheptan-2-yl]-11-hydroxy-4,4,9,13,14-pentamethyl-2,3,7,8,10,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]-3,4,5-trihydroxyoxan-2-yl]methoxy]-6-(hydroxymethyl)oxane-3,4,5-triol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~88.87 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (2.22 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (2.22 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (2.22 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.8887 mL | 4.4433 mL | 8.8866 mL | |
| 5 mM | 0.1777 mL | 0.8887 mL | 1.7773 mL | |
| 10 mM | 0.0889 mL | 0.4443 mL | 0.8887 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
